Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LFCR Lifecore Biomedical	$6.75 -1.9%	$6.52	$3.68 ▼ $7.99	$254.73M	0.65	239,739 shs	119,436 shs
PAHC Phibro Animal Health	$23.89 -0.3%	$20.69	$16.16 ▼ $26.55	$968.36M	0.62	203,501 shs	199,585 shs
RCUS Arcus Biosciences	$9.62 +0.2%	$8.36	$6.50 ▼ $18.98	$1.02B	0.88	861,792 shs	638,981 shs
WVE Wave Life Sciences	$6.75 +1.0%	$6.45	$4.25 ▼ $16.74	$1.04B	-0.92	1.31 million shs	726,792 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LFCR Lifecore Biomedical	-1.89%	-1.46%	-3.05%	+9.22%	+15.19%
PAHC Phibro Animal Health	-0.33%	-3.12%	+25.47%	+1.06%	+38.09%
RCUS Arcus Biosciences	+0.26%	+1.16%	+18.63%	+0.52%	-40.94%
WVE Wave Life Sciences	+1.05%	+8.17%	+5.30%	-28.19%	+8.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LFCR Lifecore Biomedical	1.8439 of 5 stars	2.3	2.0	0.0	0.0	2.2	4.2	0.6
PAHC Phibro Animal Health	3.7113 of 5 stars	0.8	3.0	2.5	1.1	3.5	3.3	2.5
RCUS Arcus Biosciences	2.6552 of 5 stars	4.5	1.0	0.0	0.0	2.3	2.5	0.0
WVE Wave Life Sciences	4.2963 of 5 stars	3.5	0.0	0.0	4.8	3.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	18.52% Upside
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-16.28% Downside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	150.91% Upside
WVE Wave Life Sciences	3.00	Buy	$21.17	213.58% Upside

Current Analyst Ratings Breakdown

Latest LFCR, PAHC, RCUS, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/29/2025	WVE Wave Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
4/8/2025	WVE Wave Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
3/26/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LFCR Lifecore Biomedical	$130.31M	1.92	N/A	N/A	$0.37 per share	18.24
PAHC Phibro Animal Health	$1.19B	0.81	$2.20 per share	10.87	$6.09 per share	3.92
RCUS Arcus Biosciences	$141M	7.22	N/A	N/A	$6.17 per share	1.56
WVE Wave Life Sciences	$104.94M	9.91	N/A	N/A	$0.40 per share	16.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-12.52%	-315.23%	-12.74%	8/15/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	49.77	11.38	0.45	1.75%	25.35%	6.21%	N/A
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	8/14/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.84	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	8/14/2025 (Estimated)

Latest LFCR, PAHC, RCUS, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	WVE Wave Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Latest LFCR, PAHC, RCUS, and WVE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LFCR Lifecore Biomedical	9.21	2.32	1.21
PAHC Phibro Animal Health	2.99	3.20	1.37
RCUS Arcus Biosciences	0.08	5.24	5.24
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LFCR Lifecore Biomedical	83.36%
PAHC Phibro Animal Health	99.34%
RCUS Arcus Biosciences	92.89%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
LFCR Lifecore Biomedical	32.20%
PAHC Phibro Animal Health	50.07%
RCUS Arcus Biosciences	12.30%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LFCR Lifecore Biomedical	690	37.03 million	26.58 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
WVE Wave Life Sciences	240	154.13 million	108.14 million	Optionable

LFCR, PAHC, RCUS, and WVE Headlines

Recent News About These Companies

Two Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 3 at 3:56 AM | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 31, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LP

May 29, 2025 | marketbeat.com

Bank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

May 29, 2025 | marketbeat.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Polar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 28, 2025 | marketbeat.com

845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLC

May 27, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLC

May 25, 2025 | marketbeat.com

BNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 20, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust Corp

May 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Buy" by Analysts

May 19, 2025 | marketbeat.com

Polar Capital Holdings Plc Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 18, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by D. E. Shaw & Co. Inc.

May 17, 2025 | marketbeat.com

MPM Bioimpact LLC Raises Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 16, 2025 | marketbeat.com

FY2025 EPS Estimates for WVE Increased by Cantor Fitzgerald

May 16, 2025 | marketbeat.com

Maven Securities LTD Sells 680,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

May 15, 2025 | marketbeat.com

B. Riley Has Pessimistic Outlook of WVE FY2029 Earnings

May 14, 2025 | marketbeat.com

FY2028 Earnings Estimate for WVE Issued By Wedbush

May 14, 2025 | marketbeat.com

Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR, PAHC, RCUS, and WVE Company Descriptions

Lifecore Biomedical NASDAQ:LFCR

$6.75 -0.13 (-1.89%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$6.70 -0.05 (-0.74%)

As of 04:03 AM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Phibro Animal Health NASDAQ:PAHC

$23.89 -0.08 (-0.33%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$23.89 0.00 (0.00%)

As of 06/5/2025 04:04 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Arcus Biosciences NYSE:RCUS

$9.62 +0.02 (+0.16%)

Closing price 06/5/2025 03:59 PM Eastern

Extended Trading

$9.92 +0.31 (+3.21%)

As of 04:34 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Wave Life Sciences NASDAQ:WVE

$6.75 +0.07 (+1.05%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$6.75 0.00 (0.00%)

As of 06/5/2025 04:32 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time